We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma.
- Authors
Ren, Zhenggang; Shao, Guoliang; Shen, Jie; Zhang, Li; Zhu, Xu; Fang, Weijia; Sun, Guoping; Bai, Yuxian; Wu, Jianbing; Liu, Lianxin; Yuan, Yuan; Zhang, Jingdong; Li, Zhen; Zhang, Ling; Yin, Tao; Wu, Jincai; Hou, Xiaoli; Wang, Qingyu; Zhu, Jun; Fan, Jia
- Abstract
Median duration of follow-up was 15.2 months (range, 2.0-17.8) in group A and 12.3 months (range, 1.7-16.2) in group B. Sixteen (80.0%) patients in group A and 16 (76.2%) patients in group B discontinued treatment, with PD being the main reason in both groups (Fig. The number of patients to be enrolled depended on observed toxicities; if treatment was considered well tolerated in the first 6 patients (or 12 patients if more evidence was required) during the 4-week observation period after the first dose, 20 patients were to be enrolled in each group. Among AESIs, irAEs occurred in 5 (25.0%) patients in group A and 8 (38.1%) patients in group B. Most irAEs were grade <=3; 2 (9.5%) patients in group B had grade 4 or 5 events of platelet count decrease.
- Subjects
HEPATOCELLULAR carcinoma; BEVACIZUMAB; PROGRAMMED cell death 1 receptors; HEPATITIS associated antigen; GASTROINTESTINAL hemorrhage; POSTERIOR leukoencephalopathy syndrome; RENAL cell carcinoma
- Publication
Liver Cancer (2235-1795), 2023, Vol 12, Issue 2, p1
- ISSN
2235-1795
- Publication type
Article
- DOI
10.1159/000526638